PMID- 20684309
OWN - NLM
STAT- MEDLINE
DCOM- 20121015
LR  - 20121115
IS  - 1000-3061 (Print)
IS  - 1000-3061 (Linking)
VI  - 26
IP  - 5
DP  - 2010 May
TI  - [Transplantation of atrial natriuretic peptide-expressing fibroblasts reduces 
      blood pressure and increases urine volume in spontaneously hypertensive rats].
PG  - 643-8
AB  - To investigate the potential of gene therapy for the treatment of chronic 
      diseases such as hypertension, chronic heart failure, and chronic renal failure, 
      we established the neonatal rat fibroblast line engineered to secrete the mutant 
      human atrial natriuretic peptide (mhANP), and then transplanted the cell line 
      into young spontaneously hypertensive rats (SHR) subcutaneously. We found that a 
      single transplantation of the cell line caused an obvious rise in the 
      concentration of mhANP in serum 7 d after transplantation ((135 +/- 8) vs (106 
      +/- 7) pg/mL, P < 0.01). The animals' blood pressure in test group was always 
      remarkably lower than that of empty vector group within 42 d after 
      transplantation, even though the blood pressure in all groups was constantly 
      increasing in the process of ontogeny ((175 +/- 10) mm Hg vs (189 +/- 12) mm Hg, 
      P < 0.05). A maximal blood pressure reduction of 33 mm Hg ((157 +/- 9) mm Hg vs 
      (124 +/- 112) mm Hg, P < 0.01) was observed 14 d post cell transplantation. There 
      was a marked increase in urine volume in test group from second week after 
      treatment beginning ((5.9 +/- 0.7) mL/6 h vs (4.3 +/- 0.8) mL/6 h, P < 0.01) and 
      the effect lasted 14 d ((6.1 +/- 1.1) mL/6 h vs (4.0 +/- 0.8) mL/6 h, P < 0.01), 
      however the statistical difference in concentration of K+ and Na+ in serum and 
      urine was not observed. The results suggested that subcutaneous implantation of 
      fibroblasts-expressing mhANP significantly reduced blood pressure in young SHR 
      during the period of ontogeny and efficiently improved their renal function and 
      the somatic gene transfer of mhANP may have potential value in the treatment of 
      human chronic diseases such as hypertension, chronic heart failure, and chronic 
      renal failure.
FAU - Li, Tao
AU  - Li T
AD  - National Laboratory of Medical Molecular Biology, Institute of Basic Medical 
      Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking 
      Union Medical College, Beijing 100005, China.
FAU - Liang, Hongyan
AU  - Liang H
FAU - Lu, Jinzhi
AU  - Lu J
FAU - Chen, Weijing
AU  - Chen W
FAU - Lu, Shengdong
AU  - Lu S
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Sheng Wu Gong Cheng Xue Bao
JT  - Sheng wu gong cheng xue bao = Chinese journal of biotechnology
JID - 9426463
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Animals
MH  - Atrial Natriuretic Factor/*genetics/physiology
MH  - Cell Line
MH  - Fibroblasts/cytology/*metabolism/*transplantation
MH  - Gene Expression
MH  - Genetic Therapy/*methods
MH  - Humans
MH  - Hypertension/genetics/physiopathology/*therapy
MH  - Male
MH  - Mutation
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Transfection
MH  - Urination
EDAT- 2010/08/06 06:00
MHDA- 2012/10/16 06:00
CRDT- 2010/08/06 06:00
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2012/10/16 06:00 [medline]
PST - ppublish
SO  - Sheng Wu Gong Cheng Xue Bao. 2010 May;26(5):643-8.